Screener
Theravance Biopharma TBPH Business Segments — Operating Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| (In thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total recurring operating expenses | 23,549 | 29,822 |
| Restructuring expenses (including share-based compensation) | 3,633 | — |
| Total operating expenses | 27,182 | 29,822 |
| Loss from operations | (9,483) | (14,434) |
| Interest expense (non-cash) | — | (643) |
| Interest and other income, net | 3,013 | 939 |
| Provision for income tax benefit | 1,537 | 559 |
| Net loss | $(4,933) | $(13,579) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's business segments — operating income?
- Theravance Biopharma (TBPH) reported business segments — operating income of -$9.48M in Q1 2026.
- How has Theravance Biopharma's business segments — operating income changed year-over-year?
- Theravance Biopharma's business segments — operating income increased by 34.3% year-over-year, from -$14.43M to -$9.48M.
- What does business segments — operating income mean?
- This metric represents the profit or loss generated from the core business operations of the segment, calculated by subtracting operating expenses from segment revenue. It serves as a primary indicator of the segment's operational efficiency and its ability to generate sustainable earnings before financing and tax considerations.
Ask your AI about Theravance Biopharma's business segments — operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude